? FLOW CYTOMETRY SHARED RESOURCE The Flow Cytometry (FC) shared resource supports Duke Cancer Institute (DCI) investigators with sorting and/or analyzing populations of cells based on expression of surface proteins or fluorescent reporters, and performing batch or single-cell sorting. Flow cytometry allows investigators to analyze parameters such as cell death, cell cycle, cell signaling, and cytokine production as a function of cellular state or stimulation.
Our Specific Aims are: 1) Maintain state-of-the-art cell sorters and cell analyzers in a cost-effective manner to meet DCI research needs; 2) Provide expertise in assay development, troubleshooting, and data analysis; and 3) Train DCI members to use cytometers independently. The resource maintains four analyzers, four cell sorters, and one image cytometer; analyzers and the image cytometer are available for self-use, 24 hrs per day and 365 days per year. FC staff is actively engaged in DCI member research projects, working closely with clients to fine tune their individual experiments and develop strategies for best outcomes in real time. Based on our extensive experience, we are able to recommend assays, to help develop and troubleshoot new protocols, and participate in data analysis. The FC?s experienced staff performs cell sorting, cell analysis, and post-acquisition data handling. These services would otherwise be unaffordable to investigators, given the costs, time, and training required to purchase, use, and maintain the necessary equipment. Flow cytometry services are not outsourced easily, given the fragile and time-sensitive nature of the cell preparations and the experimental protocols. An important and continuing mission of the FC resource is educating clients to ensure that all DCI members use the services and technology that best support their research goals. We provide ongoing training in the use of cytometers and associated software, and maintain a library to disseminate technical information to users. DCI members receive priority services, and FC operates on a charge-back basis with different rates for staff-run or self-run work. DCI member laboratories get added value in the form of a 25% discount on usage fees compared to non-DCI member labs. In 2018, the FC provided services to 190 investigators, 61% of whom were DCI members who accounted for 78% of total usage and represented all 8 DCI Research Programs. Use of the shared resource by DCI Members, contributed to 320 publications over the project period, 104 of which were in high impact journals (Impact Factor>9).
|Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31|
|Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741|
|Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14|
|Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :|
|Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21|
|Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260|
|Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331|
|Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131|
|Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790|
|Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408|
Showing the most recent 10 out of 513 publications